New Zealand markets closed

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
40.46-0.30 (-0.74%)
At close: 04:00PM EDT
40.46 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close40.76
Open40.77
Bid40.37 x 600
Ask40.48 x 200
Day's range39.35 - 41.01
52-week range4.82 - 48.80
Volume901,424
Avg. volume1,689,627
Market cap4.783B
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-2.95
Earnings date06 Nov 2024 - 11 Nov 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est66.80
  • PR Newswire

    Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining with patient and advocacy communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families who are impacted by neuromuscular diseases. During the month, Avidity is engaging with patient communities to

  • PR Newswire

    Avidity Biosciences to Participate in Upcoming Investor Conferences

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:

  • PR Newswire

    Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 52,100 shares of its common stock and 26,050 restricted stock units ("RSUs") to seven (7) new non-executive employees under the Avidity Biosc